Skip to main content
. 2019 Aug 30;36(4):382–391. doi: 10.5114/ada.2018.80272

Figure 2.

Figure 2

A – Vitiligo-like depigmentation after 6 months of anti-PD-1 therapy (CTCEA grade 1) within metastatic melanoma tumours on the face. B – Vitiligo-like depigmentation after 6 months of anti-PD-1 therapy (CTCEA grade 1) within the scar after excised primary melanoma lesion on the anterior surface of the left lower leg. C – Vitiligo-like depigmentation lesions within metastatic melanoma of the skin after a few months of anti-PD-1 treatment for metastatic melanoma. D – Vitiligo-like depigmentation lesions within selected melanocytic naevi after a few months of anti-PD-1 treatment for metastatic melanoma. E – Classical vitiligo-like depigmentation within the dorsal hands (CTCAE grade 1) that occurred after a few months of anti-PD-1 treatment for metastatic melanoma